GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ProPhase Labs Inc (NAS:PRPH) » Definitions » Cyclically Adjusted Price-to-FCF

ProPhase Labs (ProPhase Labs) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)


View and export this data going back to 1995. Start your Free Trial

What is ProPhase Labs Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


ProPhase Labs Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for ProPhase Labs's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProPhase Labs Cyclically Adjusted Price-to-FCF Chart

ProPhase Labs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ProPhase Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ProPhase Labs's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, ProPhase Labs's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProPhase Labs's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Cyclically Adjusted Price-to-FCF falls into.



ProPhase Labs Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

ProPhase Labs's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, ProPhase Labs's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.084/129.4194*129.4194
=-0.084

Current CPI (Dec. 2023) = 129.4194.

ProPhase Labs Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.178 99.695 0.231
201406 -0.121 100.560 -0.156
201409 -0.137 100.428 -0.177
201412 -0.125 99.070 -0.163
201503 0.132 99.621 0.171
201506 -0.112 100.684 -0.144
201509 -0.204 100.392 -0.263
201512 -0.062 99.792 -0.080
201603 0.046 100.470 0.059
201606 -0.077 101.688 -0.098
201609 -0.044 101.861 -0.056
201612 0.010 101.863 0.013
201703 0.167 102.862 0.210
201706 -0.222 103.349 -0.278
201709 -0.032 104.136 -0.040
201712 -0.141 104.011 -0.175
201803 -0.015 105.290 -0.018
201806 0.011 106.317 0.013
201809 -0.113 106.507 -0.137
201812 -0.068 105.998 -0.083
201903 0.117 107.251 0.141
201906 -0.082 108.070 -0.098
201909 -0.087 108.329 -0.104
201912 -0.041 108.420 -0.049
202003 0.015 108.902 0.018
202006 0.374 108.767 0.445
202009 -0.048 109.815 -0.057
202012 -0.710 109.897 -0.836
202103 -0.649 111.754 -0.752
202106 0.273 114.631 0.308
202109 -0.359 115.734 -0.401
202112 -0.298 117.630 -0.328
202203 1.024 121.301 1.093
202206 0.215 125.017 0.223
202209 0.103 125.227 0.106
202212 -0.048 125.222 -0.050
202303 -0.002 127.348 -0.002
202306 -0.452 128.729 -0.454
202309 -0.310 129.860 -0.309
202312 -0.084 129.419 -0.084

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ProPhase Labs  (NAS:PRPH) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


ProPhase Labs Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of ProPhase Labs's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ProPhase Labs (ProPhase Labs) Business Description

Traded in Other Exchanges
N/A
Address
711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Executives
Morse Robert A. Jr. officer: Controller 711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530
Billy Joe White officer: Chief Financial Officer 191 OTTO ST., PORT TOWNSEND WA 98368
Jason Michael Barr director 902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010
Louis Md Gleckel 10 percent owner C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042
Ted William Karkus 10 percent owner 188 HEWLETT NECK ROAD, WOODMERE NY 11598
Warren Hirsch director 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Monica L. Brady officer: Chief Accounting Officer 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Cuddihy Robert V Jr officer: Chief Operating Officer PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Mark S Leventhal 10 percent owner THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468
Mark Shawn Frank director 104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940
James T Mccubbin director
Mark A. Burnett 10 percent owner 40 HEMLOCK DRIVE, ROSLYN NY 11576
Guy J Quigley director, 10 percent owner, officer: Chairman, President, CEO C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901
John Deshazo 10 percent owner 17 WOLCOTT COURT, BOSTON MA 02136